drugset / Trial / NCT06959511

Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery

NCT06959511

Phase 2 Recruiting 45 enrolled M.D. Anderson Cancer Center Exelixis · collab
NaSingle-groupOpen-labelTreatment

Summary

To look at the effectiveness of zanzalintinib, followed by surgery, in treating advanced thyroid cancer. The safety of this treatment will also be studied.

Timeline

Start
2025-07-22
Primary completion
2028-03-01
Completion
2030-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Zanzalintinib Small molecule 60 mg Oral

Indications